Unicorn Capital Partners

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Tezign is a leading enterprise content and AI company founded in 2015, specializing in generative AI solutions for content creation and management. The company focuses on building a digital infrastructure that enhances the efficiency and quality of content production for global enterprises. Tezign has partnered with over 200 notable companies, including major brands like Alibaba, Unilever, and Procter & Gamble, and has successfully generated more than 150,000 content assets. Its platform employs advanced data technology and image recognition to connect top designers with businesses, facilitating marketing content production and optimization. Additionally, Tezign has cultivated a content ecosystem comprising over 100,000 content creators, establishing a significant scale in content asset management.

Botkin.AI is a Moscow-based company established in 2015. It develops an AI-driven platform for medical image processing and analysis, focusing on tumor risk assessment using deep learning algorithms. The platform enhances radiologists' diagnostic capabilities and accelerates patient data processing without compromising conclusion quality.